{"url_path":"/sec/acrv/8-k/2026-06-17/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/1781174/0001193125-26-274410-index.html","accession_number":"0001193125-26-274410","cik":"0001781174","ticker":"ACRV","issuer_name":"Acrivon Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1781174/0001193125-26-274410-index.html","primary_entity_key":"0001781174","primary_entity_name":"Acrivon Therapeutics, Inc."},"word_count":84,"has_tables":true,"body_markdown":"## Item 9.01 Financial Statements and Exhibits.\n\nExhibit\n\nNumber\n\nDescription\n\n10.1\n\n[Amended and Restated 2022 Equity Incentive Plan](acrv-ex10_1.htm)\n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nAcrivon Therapeutics, Inc.\n\n \n\n \n\n \n\n \n\nDate:\n\nJune 17, 2026\n\nBy:\n\n/s/ Peter Blume-Jensen, M.D., Ph.D.\n\n \n\n \n\n \n\nName: Peter Blume-Jensen, M.D., Ph.D.\nTitle: Chief Executive Officer and President"}